Клиническая задача и разбор №14. Пациентка с сахарным диабетом 2-го типа и хронической сердечной недостаточностью
- Количество записей: 37
-
- По дате
- По просмотрам
-
Зарубежные материалы
Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial
In patients with chronic heart failure (CHF) and reduced left ventricular ejection fraction (LVEF), angiotensin-converting enzyme inhibitors, beta-blockers, and spironolactone reduce mortality and improve LVEF. However, long-term survival and quality of life remain markedly impaired, especially in patients with diabetes. We therefore need new, safe treatment modalities that can improve CHF symptom ...
Подробнее
721
-
Зарубежные материалы
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
The effects of empagliflozin, an inhibitor of sodium–glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.
Подробнее
720
-
Зарубежные материалы
Pioglitazone Initiation and Subsequent Hospitalisation for Congestive Heart Failure
Thiazolidinediones (TZD) have been associated with an expansion in plasma volume and the development of peripheral oedema. A recent study reported an association between the use of TZDs and development of congestive heart failure (CHF). The objective of this study was todetermine if short-term use of pioglitazone, a TZD, is associated with increased risk of CHF hospitalisation in a well-character ...
Подробнее
606
-
Статьи
-
Зарубежные материалы
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The extent to which diabetes mellitus or hyperglycemia is related to risk of death from cancer or other nonvascular conditions is uncertain.
Подробнее
604
-
Зарубежные материалы
The effects of postnatal health education for mothers on infant care and family planning practices in Nepal: a randomised controlled trial
Mothers in groups A and B (received health education at birth) were slightly more likely to use contraception at six months after birth compared with mothers in groups C and D (no health education at birth) (odds ratio 1.62, 95% confidence interval 1.06 to 2.5). There were no other significant differences between groups with regards to infant feeding, infant care, or immunisation.
Подробнее
505
-
Зарубежные материалы
-
Зарубежные материалы
Obesity : preventing and managing the global epidemic : report of a WHO Consultation on Obesity, Geneva, 3-5 June 1997
WHO Consultation on Obesity (1997: Geneva, Switzerland), World Health Organization. Division of Noncommunicable Diseases & World Health Organization. Programme of Nutrition, Family and Reproductive Health. (1998). Obesity : preventing and managing the global epidemic : report of a WHO Consultation on Obesity, Geneva, 3-5 June 1997. World Health Organization.
Подробнее
605
-
Зарубежные материалы
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes
Fifteen years ago, a panel of experts representing the full spectrum of cardiovascular disease (CVD) research and practice assembled at a workshop to examine the state of knowledge about CVD. The leaders of the workshop generated a hypothesis that framed CVD as a chain of events, initiated by a myriad of related and unrelated risk factors and progressing through numerous physiological pathways and ...
Подробнее
532
-
Зарубежные материалы
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
Lorcaserin, a selective serotonin 2C receptor agonist that modulates appetite, has proven efficacy for weight management in overweight or obese patients. The cardiovascular safety and efficacy of lorcaserin are undefined.
Подробнее
677
-
Зарубежные материалы
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study
After matching, a total of 40 908 patients with T2D were identified as new users of dapagliflozin (n = 10 227) or a DPP-4 inhibitor (n = 30 681). The groups were well balanced at baseline; their mean age was 61 years and 23% had CV disease. The mean follow-up time was 0.95 years, with a total of 38 760 patient-years. Dapagliflozin was associated with a lower risk of MACE, HHF and all-cause mortal ...
Подробнее
767
-
Зарубежные материалы
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the composite end point of cardiovascular death/hospitalization for heart failure (HHF) in a broad population of patients with type 2 diabetes mellitus. However, the impact of baseline left ventricular ejection fraction (EF) ...
Подробнее
598
-
Зарубежные материалы
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium – glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined.
Подробнее
674
-
Зарубежные материалы
Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
Intensified multifactorial intervention — with tight glucose regulation and the use of renin–angiotensin system blockers, aspirin, and lipid-lowering agents — has been shown to reduce the risk of nonfatal cardiovascular disease among patients with type 2 diabetes mellitus and microalbuminuria. We evaluated whether this approach would have an effect on the rates of death from any cause and from ca ...
Подробнее
565
-
Зарубежные материалы
Obesity. preventing and managing the global epidemic. 1997, Geneva. WHO. p. 159-276
WHO Consultation on Obesity (1997: Geneva, Switzerland), World Health Organization. Division of Noncommunicable Diseases & World Health Organization. Programme of Nutrition, Family and Reproductive Health. (1998). Obesity : preventing and managing the global epidemic : report of a WHO Consultation on Obesity, Geneva, 3-5 June 1997. World Health Organization.
Подробнее
621
- ← Предыдущая
- 1
- 2 (current)
- 3
- Следующая →